Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 11, 2013, Pages 1101-1106

  Izzo, R ^a   De Simone, G ^a   Trimarco, V ^a   Giudice, R ^a   De Marco, M ^a   Di Renzo, G ^a   De Luca, N ^a   Trimarco, B ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CV risk; Diabetes; Statins

Indexed keywords

ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE;

CV RISK; DIABETES; STATINS;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INCIDENCE; ITALY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PRIMARY PREVENTION; RISK FACTORS; SEX CHARACTERISTICS; TERTIARY CARE CENTERS;

EID: 84887617769     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.11.002     Document Type: Article

References (34)

1. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Danaei G., Lawes C.M., Vander Hoorn S., Murray C.J., Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006, 368:1651-1659.
3. Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S., Murray C.J. Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-1360.
4. Brancati F.L., Kao W.H., Folsom A.R., Watson R.L., Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the atherosclerosis risk in communities study. JAMA 2000, 283:2253-2259.
5. Izzo R., de Simone G., Chinali M., Iaccarino G., Trimarco V., Rozza F., et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009, 32:845-850.
6. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
7. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
8. Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
9. Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
10. De Luca N., Izzo R., Iaccarino G., Malini P.L., Morisco C., Rozza F., et al. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens 2005, 23:1417-1423.
11. Hallan S., Asberg A., Lindberg M., Johnsen H. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004, 44:84-93.
12. de Simone G., Izzo R., Chinali M., De Marco M., Casalnuovo G., Rozza F., et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension?. Hypertension 2010, 56:99-104.
13. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
14. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
15. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
16. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
17. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
18. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
19. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
20. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
21. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
22. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
23. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 2001, 103:357-362.
24. Keech A., Colquhoun D., Best J., Kirby A., Simes R.J., Hunt D., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
25. Thongtang N., Ai M., Otokozawa S., Himbergen T.V., Asztalos B.F., Nakajima K., et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 2011, 107:387-392.
26. Yusuf S., Lonn E., Bosch J. Lipid lowering for primary prevention. Lancet 2009, 373:1152-1155.
27. Lenfant C. Shattuck lecture - clinical research to clinical practice - lost in translation?. N Engl J Med 2003, 349:868-874.
28. Egger M., Smith G.D. Misleading meta-analysis. BMJ 1995, 311:753-754.
29. Easterbrook P.J., Berlin J.A., Gopalan R., Matthews D.R. Publication bias in clinical research. Lancet 1991, 337:867-872.
30. Egger M., Smith G.D. Bias in location and selection of studies. BMJ 1998, 316:61-66.
31. Egger M., Zellweger-Zahner T., Schneider M., Junker C., Lengeler C., Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997, 350:326-329.
32. Gotzsche P.C. Reference bias in reports of drug trials. Br Med J (Clin Res Ed) 1987, 295:654-656.
33. Sheikh K. Statins and risk of incident diabetes. Lancet 2010, 375:2139-2140. author reply 41-2.
34. Tooke J.E. Microvascular function in human diabetes. A physiological perspective. Diabetes 1995, 44:721-726.